Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2

AGIOS PHARMACEUTICALS, INC.

2024-Q1 EPS reported -$1.45 revenue$8,189,000

PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.
Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.
Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.
ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.
Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2024 results: revenue $8.2 million.

Period: the first quarter ended March 31, 2024
Revenue: $8.2 million
Result: reported results

Exact text from the filing

RISE UP Study in Sickle Cell Disease, ACTIVATE-KIDS and ACTIVATE KIDS-T in Pediatric PK Deficiency, All Expected by End of 2025 – – PYRUKYND® (Mitapivat) Net Revenue of $8.2 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $714.3 Million as of March 31, 2024 – CAMBRIDGE, Mass., May 2, 2024 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-24-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.